The skin should be clean, dry, and free from cuts, irritation, rashes, or excessive hair
Learn More Submit Now Click through the PLOS taxonomy to find articles in your field
mechanistic and exploratory, not a clinical efficacy trial
MOTS-c and NAD+ work differently but overlap in one key area: MOTS-c increases cellular NAD+ levels as part of its mechanism, which means stacking both compounds can create a synergistic effect rather than a redundant one
Targeting GLP-1 receptor trafficking to improve agonist efficacy
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks